 Shares of NeoGenomics NASDAQ:NEO rose 1 after the company reported Q2 results.Quarterly Results Earnings per share fell 157.14 over the past year to 0.04, which beat the estimate of 0.10.Revenue of 86,977,000 decreased by 14.49 from the same period last year, which beat the estimate of 86,120,000.Guidance Earnings guidance hasnt been issued by the company for now.Revenue guidance hasnt been issued by the company for now.Conference Call Details Date: Jul 28, 2020View more earnings on NEOTime: 08:30 AMET Webcast URL: Action 52-week high: 37.7052-week low: 18.52Price action over last quarter: Up 18.70Company Overview NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Pharma Services. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. The company generates revenue from Clinical Services.See more from Benzinga Earnings Scheduled For July 28, 2020 Stocks That Hit 52-Week Highs On Friday Stocks That Hit 52-Week Highs On ThursdayC 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 